

REFERENCES

- Alefshat, E., Jelinek, H., Mousa, M., Tay, G., & Alsafar, H. (2022). Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. *Journal Of Infection And Public Health*, 15(2), 277-288.
- Allele frequencies.net. 2021. The Allele Frequency Net Database - Allele, haplotype and genotype frequencies in Worldwide Populations. [online] Available at: <<http://www.allelefrequencies.net/>>.
- Amanat, F., & Krammer, F. (2020). SARS-CoV-2 Vaccines: Status Report. *Immunity*, 52(4), 583-589. doi: 10.1016/j.immuni.2020.03.007
- Astuti, I. and Ysrafil, 2020. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 14(4), pp.407-412.
- Azzi, L., Carcano, G., Gianfagna, F., Grossi, P., Gasperina, D., & Genoni, A. et al. (2020). Saliva is a reliable tool to detect SARS-CoV-2. *Journal Of Infection*, 81(1), e45-e50. doi: 10.1016/j.jinf.2020.04.005
- Behjati, S., & Tarpey, P. (2013). What is next generation sequencing?. *Archives Of Disease In Childhood - Education & Practice Edition*, 98(6), 236-238.
- Brant, A., Tian, W., Majerciak, V., Yang, W. and Zheng, Z., 2021. SARS-CoV-2: from its discovery to genome structure, transcription, and replication. *Cell & Bioscience*, 11(1).
- Centers for Disease Control and Prevention. 2021. Coronavirus Disease 2019 (COVID-19). Available at: <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#anchor_1632154493691>.
- Chen, X., Kang, Y., Luo, J., Pang, K., Xu, X., Wu, J., Li, X. and Jin, S., 2021. Next-Generation Sequencing Reveals the Progression of COVID-19. *Frontiers in Cellular and Infection Microbiology*, 11.
- Chiara, M., D'Erchia, A., Gissi, C., Manzari, C., Parisi, A., Resta, N., Zambelli, F., Picardi, E., Pavesi, G., Horner, D. and Pesole, G., 2020. Next generation sequencing of SARS-CoV-2 genomes: challenges, applications and opportunities. *Briefings in Bioinformatics*, 22(2), pp.616-630.

Class I Immunogenicity. (2022). From <http://tools.iedb.org/immunogenicity/>

Creech, C., Walker, S. and Samuels, R., 2021. SARS-CoV-2 Vaccines. *JAMA*, 325(13), p.1318.

Cun, Y., Li, C., Shi, L., Sun, M., Dai, S., & Sun, L. et al. (2020). COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations. *Human Vaccines & Immunotherapeutics*, 17(4), 1097-1108. doi: 10.1080/21645515.2020.1823777

Dearlove, B., Lewitus, E., Bai, H., Li, Y., Reeves, D., & Joyce, M. et al. (2020). A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. *Proceedings Of The National Academy Of Sciences*, 117(38), 23652-23662. doi: 10.1073/pnas.2008281117

Delbue, S., D'Alessandro, S., Signorini, L., Dolci, M., Pariani, E., & Bianchi, M. et al. (2021). Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a stop codon in the ORF 6 protein. *Emerging Microbes & Infections*, 10(1), 252-255.

dos Santos, W., 2021. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. *Biomedicine & Pharmacotherapy*, 136, p.111272.

Dyer, O. (2021). Covid-19: Indonesia becomes Asia's new pandemic epicentre as delta variant spreads.

Fatoba, A., Maharaj, L., Adeleke, V., Okpeku, M., Adeniyi, A., & Adeleke, M. (2021). Immunoinformatics prediction of overlapping CD8+ T-cell, IFN- γ and IL-4 inducer CD4+ T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2). *Vaccine*, 39(7), 1111-1121.

Gisaid.org. 2021. GISAID - Initiative. [online] Available at: <<https://www.gisaid.org/>>.

Grifoni, A., Sidney, J., Vita, R., Peters, B., Crotty, S., Weiskopf, D. and Sette, A., 2021. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. *Cell Host & Microbe*, 29(7), pp.1076-1092.

Gustiananda, M., Sulistyono, B., Agustriawan, D., & Andarini, S. (2021). Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population. *Vaccines*, 9(12), 1459.

Hassan, S., Aljabali, A., Panda, P., Ghosh, S., Attrish, D., & Choudhury, P. et al. (2021). A unique view of SARS-CoV-2 through the lens of ORF8 protein. *Computers In Biology And Medicine*, 133, 104380.

Hassan, S., Choudhury, P., & Roy, B. (2021). Rare mutations in the accessory proteins ORF6, ORF7b, and ORF10 of the SARS-CoV-2 genomes. *Meta Gene*, 28, 100873.

<https://www.healthtech.dtu.dk>. 2021. Services. [online] Available at: <<https://services.healthtech.dtu.dk/service.php?NetCTLpan-1.1>>.

<https://www.healthtech.dtu.dk>. 2021. Services. [online] Available at: <<https://services.healthtech.dtu.dk/service.php?NetMHCIIPan-4.0>>.

IFNepitope: A server for predicting and designing IFN-gamma inducing epitopes. (2022). From <http://crdd.osdd.net/raghava/ifnepitope/scan.php>

Jackson, C., Zhang, L., Farzan, M. and Choe, H., 2021. Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. *Biochemical and Biophysical Research Communications*, 538, pp.108-115.

Kevadiya, B., Machhi, J., Herskovitz, J., Oleynikov, M., Blomberg, W., Bajwa, N., Soni, D., Das, S., Hasan, M., Patel, M., Senan, A., Gorantla, S., McMillan, J., Edagwa, B., Eisenberg, R., Gurumurthy, C., Reid, S., Punyadeera, C., Chang, L. and Gendelman, H., 2021. Diagnostics for SARS-CoV-2 infections. *Nature Materials*, 20(5), pp.593-605.

Khailany, R., Safdar, M. and Ozaslan, M., 2020. Genomic characterization of a novel SARS-CoV-2. *Gene Reports*, 19, p.100682.

Lambrou, A., Shirk, P., Steele, M., Paul, P., Paden, C., & Cadwell, B. et al. (2022). Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022. *MMWR. Morbidity And Mortality Weekly Report*, 71(6), 206-211.

Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., Zhang, Q. and Wu, J., 2020. Coronavirus infections and immune responses. *Journal of Medical Virology*, 92(4), pp.424-432.

Lon, J. R., Bai, Y., Zhong, B., Cai, F., & Du, H. (2020). Prediction and evolution of B cell epitopes of surface protein in SARS-CoV-2. *Virology journal*, 17(1), 1-9.

Markosian, C., Staquicini, D., Dogra, P., Dodero-Rojas, E., Lubin, J., & Tang, F. et al. (2022). Genetic and

- Structural Analysis of SARS-CoV-2 Spike Protein for Universal Epitope Selection. *Molecular Biology And Evolution*, 39(5).
- Matsumura, M., Fremont, D., Peterson, P. and Wilson, I., 1992. Emerging Principles for the Recognition of Peptide Antigens by MHC Class I Molecules. *Science*, 257(5072), pp.927-934.
- Michel, C., Mayer, C., Poch, O., & Thompson, J. (2020). Characterization of accessory genes in coronavirus genomes. *Virology Journal*, 17(1). doi: 10.1186/s12985-020-01402-1
- Montes-Grajales, D. and Olivero-Verbel, J., 2021. Bioinformatics Prediction of SARS-CoV-2 Epitopes as Vaccine Candidates for the Colombian Population. *Vaccines*, 9(7), p.797.
- Naqvi, A., Fatima, K., Mohammad, T., Fatima, U., Singh, I., & Singh, A. et al. (2020). Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. *Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease*, 1866(10), 165878.
- Nelde, A., Bilich, T., Heitmann, J., Maringer, Y., Salih, H., & Roerden, M. et al. (2020). SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. *Nature Immunology*, 22(1), 74-85. doi: 10.1038/s41590-020-00808-x
- Nemudryi, A., Nemudraia, A., Wiegand, T., Nichols, J., Snyder, D., & Hedges, J. et al. (2021). SARS-CoV-2 genomic surveillance identifies naturally occurring truncations of ORF7a that limit immune suppression.
- Ophinni Y, Hasibuan AS, Widhani A, Maria S, Koesnoe S, Yuniastuti E, Karjadi TH, Rengganis I, Djauzi S. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia. *Acta Med Indones*. 2020 Oct;52(4):388-412. PMID: 33377885.
- ORF3a ORF3a protein [Severe acute respiratory syndrome coronavirus 2] - Gene - NCBI. (2021). Retrieved 21 September 2021, from <https://www.ncbi.nlm.nih.gov/gene/4374056>
- Ortiz-Prado, E., Simbaña-Rivera, K., Gómez- Barreno, L., Rubio-Neira, M., Guaman, L., Kyriakidis, N., Muslin, C., Jaramillo, A., Barba-Ostria, C., Cevallos-Robalino, D., Sanches-SanMiguel, H., Unigarro, L., Zalakeviciute, R., Gadian, N. and López-Cortés, A., 2020. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. *Diagnostic Microbiology and Infectious Disease*,

98(1), p.115094.

- Plante, J., Liu, Y., Liu, J., Xia, H., Johnson, B., Lokugamage, K., Zhang, X., Muruato, A., Zou, J., Fontes-Garfias, C., Mirchandani, D., Scharton, D., Bilello, J., Ku, Z., An, Z., Kalveram, B., Freiberg, A., Menachery, V., Xie, X., Plante, K., Weaver, S. and Shi, P., 2020. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature*, 592(7852), pp.116-121.
- Poland, G., Ovsyannikova, I., Crooke, S. and Kennedy, R., 2020. SARS-CoV-2 Vaccine Development: Current Status. *Mayo Clinic Proceedings*, 95(10), pp.2172-2188.
- Rabi, F., Al Zoubi, M., Kasasbeh, G., Salameh, D. and Al-Nasser, A., 2021. SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far.
- Redondo, N., Zaldívar-López, S., Garrido, J., & Montoya, M. (2021). SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns. *Frontiers In Immunology*, 12. doi: 10.3389/fimmu.2021.708264
- Rizzo, J. and Buck, M., 2012. Key Principles and Clinical Applications of “Next-Generation” DNA Sequencing. *Cancer Prevention Research*, 5(7), pp.887-900.
- Satarker, S. and Nampootheri, M., 2020. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. *Archives of Medical Research*, 51(6), pp.482-491.
- Schroeder, S., Pott, F., Niemeyer, D., Veith, T., Richter, A., & Muth, D. et al. (2021). Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics. *The Lancet Microbe*, 2(5), e210-e218.
- Schrörs, B., Riesgo-Ferreiro, P., Sorn, P., Gudimella, R., Bukur, T., Rösler, T., Löwer, M. and Sahin, U., 2021. Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates. *PLOS ONE*, 16(9), p.e0249254.
- Shahhosseini, N., Babuadze, G., Wong, G. and Kobinger, G., 2021. Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern. *Microorganisms*, 9(5), p.926.
- Shah, V., Fimal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020). Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. *Frontiers In Immunology*, 11. doi: 10.3389/fimmu.2020.01949

- Smith, C., Olsen, K., Gentry, K., Sambade, M., Beck, W., & Garness, J. et al. (2021). Landscape and selection of vaccine epitopes in SARS-CoV-2. *Genome Medicine*, 13(1).
- Tools.iedb.org. 2021. Epitope Conservancy Analysis. [online] Available at: <<http://tools.iedb.org/conservancy/>>.
- V'kovski, P., Kratzel, A., Steiner, S., Stalder, H. and Thiel, V., 2020. Coronavirus biology and replication: implications for SARS-CoV-2. *Nature Reviews Microbiology*, 19(3), pp.155-170.
- Walls, A., Park, Y., Tortorici, M., Wall, A., McGuire, A. and Veesler, D., 2020. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*, 181(2), pp.281-292.e6.
- Wang, H., Li, X., Li, T., Zhang, S., Wang, L., Wu, X. and Liu, J., 2020. The genetic sequence, origin, and diagnosis of SARS-CoV-2. *European Journal of Clinical Microbiology & Infectious Diseases*, 39(9), pp.1629-1635.
- Web.expasy.org. 2021. ExPASy - Translate tool. [online] Available at: <<https://web.expasy.org/translate/>>.
- Who.int. 2021. Tracking SARS-CoV-2 variants. Available at: <<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>>.
- Wieczorek, M., Abualrous, E., Sticht, J., Álvaro-Benito, M., Stolzenberg, S., Noé, F. and Freund, C., 2017. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. *Frontiers in Immunology*, 8.
- Yadav, R., Chaudhary, J., Jain, N., Chaudhary, P., Khanra, S., & Dhamija, P. et al. (2021). Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. *Cells*, 10(4), 821. doi: 10.3390/cells10040821
- Zinzula, L. (2021). Lost in deletion: The enigmatic ORF8 protein of SARS-CoV-2. *Biochemical And Biophysical Research Communications*, 538, 116-124.

APPENDIX

Appendix 1. The SARS-CoV-2 variants from the circulating SARS-CoV-2 genome sequences collected from GISAID within the time period from October 2021 to January 2022.

Months	Date	Sample Accession ID	SARS-CoV-2 Variant
October 2021	01/10/2021	EPI_ISL_5200491	VOC Delta GK (B.1.617.2+AY.*)
	04/10/2021	EPI_ISL_5200492	VOC Delta GK (B.1.617.2+AY.*)
	04/10/2021	EPI_ISL_5200497	VOC Delta GK (B.1.617.2+AY.*)
	04/10/2021	EPI_ISL_5200498	VOC Delta GK (B.1.617.2+AY.*)
	08/10/2021	EPI_ISL_5462141	VOC Delta GK (B.1.617.2+AY.*)
	15/10/2021	EPI_ISL_5881289	VOC Delta GK (B.1.617.2+AY.*)
	15/10/2021	EPI_ISL_5881290	VOC Delta GK (B.1.617.2+AY.*)
	14/10/2021	EPI_ISL_5881291	VOC Delta GK (B.1.617.2+AY.*)
	14/10/2021	EPI_ISL_5881292	VOC Delta GK (B.1.617.2+AY.*)
	20/10/2021	EPI_ISL_5881293	VOC Delta GK (B.1.617.2+AY.*)
	19/10/2021	EPI_ISL_5881294	VOC Delta GK (B.1.617.2+AY.*)
	15/10/2021	EPI_ISL_5881295	VOC Delta GK (B.1.617.2+AY.*)
	28/10/2021	EPI_ISL_6181862	VOC Delta GK (B.1.617.2+AY.*)
	28/10/2021	EPI_ISL_6181863	VOC Delta GK (B.1.617.2+AY.*)
	25/10/2021	EPI_ISL_6181864	VOC Delta GK (B.1.617.2+AY.*)
	31/10/2021	EPI_ISL_6181865	VOC Delta GK (B.1.617.2+AY.*)
	21/10/2021	EPI_ISL_6181868	VOC Delta GK (B.1.617.2+AY.*)
	15/10/2021	EPI_ISL_6181869	VOC Delta GK (B.1.617.2+AY.*)
	13/10/2021	EPI_ISL_6181883	VOC Delta GK (B.1.617.2+AY.*)
	23/10/2021	EPI_ISL_6181895	VOC Delta GK (B.1.617.2+AY.*)
	01/10/2021	EPI_ISL_6181898	VOC Delta GK (B.1.617.2+AY.*)
	19/10/2021	EPI_ISL_6181899	VOC Delta GK (B.1.617.2+AY.*)
	21/10/2021	EPI_ISL_6181900	VOC Delta GK (B.1.617.2+AY.*)
	21/10/2021	EPI_ISL_6181901	VOC Delta GK (B.1.617.2+AY.*)
	30/10/2021	EPI_ISL_7541680	VOC Delta GK (B.1.617.2+AY.*)
	November 2021	25/11/2021	EPI_ISL_7467963

	25/11/2021	EPI_ISL_7467964	VOC Delta GK (B.1.617.2+AY.*)
	27/11/2021	EPI_ISL_7541580	VOC Delta GK (B.1.617.2+AY.*)
	28/11/2021	EPI_ISL_7541592	VOC Delta GK (B.1.617.2+AY.*)
	25/11/2021	EPI_ISL_7541604	VOC Delta GK (B.1.617.2+AY.*)
	28/11/2021	EPI_ISL_7541621	VOC Delta GK (B.1.617.2+AY.*)
	28/11/2021	EPI_ISL_7541633	VOC Delta GK (B.1.617.2+AY.*)
	02/11/2021	EPI_ISL_7541643	VOC Delta GK (B.1.617.2+AY.*)
	29/11/2021	EPI_ISL_7541657	VOC Delta GK (B.1.617.2+AY.*)
	26/11/2021	EPI_ISL_7541694	VOC Delta GK (B.1.617.2+AY.*)
	29/11/2021	EPI_ISL_7541705	VOC Delta GK (B.1.617.2+AY.*)
	29/11/2021	EPI_ISL_7541720	VOC Delta GK (B.1.617.2+AY.*)
	30/11/2021	EPI_ISL_7541729	VOC Delta GK (B.1.617.2+AY.*)
	30/11/2021	EPI_ISL_7541739	VOC Delta GK (B.1.617.2+AY.*)
	30/11/2021	EPI_ISL_8090760	VOC Delta GK (B.1.617.2+AY.*)
	24/11/2021	EPI_ISL_8315348	VOC Delta GK (B.1.617.2+AY.*)
	25/11/2021	EPI_ISL_8315357	VOC Delta GK (B.1.617.2+AY.*)
	25/11/2021	EPI_ISL_8315364	VOC Delta GK (B.1.617.2+AY.*)
	27/11/2021	EPI_ISL_8315365	VOC Delta GK (B.1.617.2+AY.*)
	22/11/2021	EPI_ISL_8315368	VOC Delta GK (B.1.617.2+AY.*)
	22/11/2021	EPI_ISL_8315370	VOC Delta GK (B.1.617.2+AY.*)
	22/11/2021	EPI_ISL_8315371	VOC Delta GK (B.1.617.2+AY.*)
	16/11/2021	EPI_ISL_8315373	VOC Delta GK (B.1.617.2+AY.*)
	24/11/2021	EPI_ISL_8315375	VOC Delta GK (B.1.617.2+AY.*)
	25/11/2021	EPI_ISL_8315376	VOC Delta GK (B.1.617.2+AY.*)
December 2021	05/12/2021	EPI_ISL_7467961	VOC Delta GK (B.1.617.2+AY.*)
	04/12/2021	EPI_ISL_8090757	VOC Delta GK (B.1.617.2+AY.*)
	04/12/2021	EPI_ISL_8090758	VOC Delta GK (B.1.617.2+AY.*)
	04/12/2021	EPI_ISL_8090759	VOC Delta GK (B.1.617.2+AY.*)
	03/12/2021	EPI_ISL_8090761	VOC Delta GK (B.1.617.2+AY.*)
	06/12/2021	EPI_ISL_8090762	VOC Delta GK (B.1.617.2+AY.*)

	13/12/2021	EPI_ISL_8131148	VOC Delta GK (B.1.617.2+AY.*)
	14/12/2021	EPI_ISL_8131149	VOC Delta GK (B.1.617.2+AY.*)
	15/12/2021	EPI_ISL_8131150	VOC Delta GK (B.1.617.2+AY.*)
	15/12/2021	EPI_ISL_8131151	VOC Delta GK (B.1.617.2+AY.*)
	15/12/2021	EPI_ISL_8131152	VOC Delta GK (B.1.617.2+AY.*)
	20/12/2021	EPI_ISL_8131154	VOC Delta GK (B.1.617.2+AY.*)
	20/12/2021	EPI_ISL_8131155	VOC Delta GK (B.1.617.2+AY.*)
	27/12/2021	EPI_ISL_8315328	VOC Delta GK (B.1.617.2+AY.*)
	23/12/2021	EPI_ISL_8315333	VOC Delta GK (B.1.617.2+AY.*)
	16/12/2021	EPI_ISL_8315359	VOC Delta GK (B.1.617.2+AY.*)
	15/12/2021	EPI_ISL_8315360	VOC Delta GK (B.1.617.2+AY.*)
	15/12/2021	EPI_ISL_8315361	VOC Delta GK (B.1.617.2+AY.*)
	05/12/2021	EPI_ISL_8315363	VOC Delta GK (B.1.617.2+AY.*)
	15/12/2021	EPI_ISL_8315377	VOC Delta GK (B.1.617.2+AY.*)
	20/12/2021	EPI_ISL_8315378	VOC Delta GK (B.1.617.2+AY.*)
	20/12/2021	EPI_ISL_8315379	VOC Delta GK (B.1.617.2+AY.*)
	20/12/2021	EPI_ISL_8315380	VOC Delta GK (B.1.617.2+AY.*)
	17/12/2021	EPI_ISL_8443104	VOC Delta GK (B.1.617.2+AY.*)
	14/12/2021	EPI_ISL_9846709	VOC Delta GK (B.1.617.2+AY.*)
January 2022	06/01/2022	EPI_ISL_8646933	VOC Delta GK (B.1.617.2+AY.*)
	08/01/2022	EPI_ISL_8646949	VOC Delta GK (B.1.617.2+AY.*)
	09/01/2022	EPI_ISL_8798995	VOC Delta GK (B.1.617.2+AY.*)
	09/01/2022	EPI_ISL_8799014	VOC Delta GK (B.1.617.2+AY.*)
	07/01/2022	EPI_ISL_8879265	VOC Delta GK (B.1.617.2+AY.*)
	11/01/2022	EPI_ISL_8886889	VOC Delta GK (B.1.617.2+AY.*)
	14/01/2022	EPI_ISL_8930073	VOC Omicron GRA (B.1.1.529+BA.*)
	14/01/2022	EPI_ISL_9019278	VOC Omicron GRA (B.1.1.529+BA.*)
	14/01/2022	EPI_ISL_9019279	VOC Omicron GRA (B.1.1.529+BA.*)
	10/01/2022	EPI_ISL_9019325	VOC Delta GK (B.1.617.2+AY.*)
10/01/2022	EPI_ISL_9019326	VOC Delta GK (B.1.617.2+AY.*)	

	10/01/2022	EPI_ISL_9019327	VOC Delta GK (B.1.617.2+AY.*)
	16/01/2022	EPI_ISL_9019496	VOC Delta GK (B.1.617.2+AY.*)
	23/01/2022	EPI_ISL_9650486	VOC Delta GK (B.1.617.2+AY.*)
	04/01/2022	EPI_ISL_9846713	VOC Delta GK (B.1.617.2+AY.*)
	04/01/2022	EPI_ISL_9846715	VOC Delta GK (B.1.617.2+AY.*)
	04/01/2022	EPI_ISL_9846716	VOC Delta GK (B.1.617.2+AY.*)
	07/01/2022	EPI_ISL_9846717	VOC Delta GK (B.1.617.2+AY.*)
	14/01/2022	EPI_ISL_9846718	VOC Delta GK (B.1.617.2+AY.*)
	04/01/2022	EPI_ISL_9846719	VOC Delta GK (B.1.617.2+AY.*)
	14/01/2022	EPI_ISL_9846720	VOC Delta GK (B.1.617.2+AY.*)
	14/01/2022	EPI_ISL_9846721	VOC Delta GK (B.1.617.2+AY.*)
	02/01/2022	EPI_ISL_9846722	VOC Delta GK (B.1.617.2+AY.*)
	14/01/2022	EPI_ISL_9846723	VOC Delta GK (B.1.617.2+AY.*)
	04/01/2022	EPI_ISL_9846724	VOC Delta GK (B.1.617.2+AY.*)